HarmeeCare Pharmaceuticals → Kilitch Estro Biotech

Why this matters

Kilitch Drugs (India) Limited has agreed to sell its entire shareholding in Kilitch Estro Biotech PLC, its Ethiopian subsidiary, to HarmeeCare Pharmaceuticals, an Ethiopian state-owned enterprise, for US$14 million. Completion is expected by 31 January 2027.

This is the reverse of the usual African localization story. Instead of a foreign manufacturer building or buying into a local plant, a mid-sized Indian generics company is handing its Ethiopian operation to the state. For Ethiopia, which has made local pharmaceutical manufacturing a policy priority to cut its import bill, the deal brings an operating facility and an existing public-tender supplier under national ownership. For Indian exporters, it shows how hard it is for a small foreign player to run an African plant profitably alongside a capital-hungry home expansion.